For example, the FANCF deficient ovarian tumor cell line, 2008+vector cells exhibited an approximately a two- to three-fold decrease in survival as compared to the FA proficient 2008+FANCF cells to BCNU or TMZ [7]. This evidence concerns the gene FANCF and ovarian neoplasm.